Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 1, 2012Current OncologyOpen Access

egfr Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

View Full Paper
Ask AI
Bookmark
Share

Authors

BMB. MeloskyBC Cancer Agency

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

B. Melosky (2012) studied this question.

synapsesocial.com/papers/6aaf710bdbd38d508e34fcaahttps://doi.org/10.3747/co.19.955
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma2009 · 8,326 citations
  2. 2Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial2009 · 493 citations
  3. 3Erlotinib in Previously Treated Non–Small-Cell Lung Cancer2005 · 5,464 citations
  4. 4American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 20032003 · 1,428 citations
  5. 5Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer2006 · 706 citations